Pharma and healthcare: sector news on Saturday 21 November 2026
Average tone +5.8 (positive) across 5 companies with relevant coverage, from 29 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +7.0 | 12 | Coverage was mostly about regulatory progress, with a priority review in the US for its gastric cancer drug and a positive EU opinion for Baxfendy, alongside a new SAP partnership. |
| GSK | +7.2 | 11 | Coverage was mainly positive, led by FDA approval of a lung cancer treatment and an early approval for Nelkarmi. |
| Convatec | +8.7 | 3 | Coverage centres on Convatec's trading update, with an upgraded guidance outlook and quicker growth in infusion care. |
| Haleon | +0.8 | 2 | Coverage of Haleon was limited to two commentary pieces, one on the FTSE index reshuffle and one on whether its cash flow is undervalued. |
| Smith & Nephew | +5.3 | 1 | Coverage was limited to a single valuation piece suggesting the shares may be trading below what its cash flow would justify. |
Strongest stories in the sector
- +10.0 Raised outlook and faster growth in infusion business favour the company.
- +10.0 Regulator fast-tracks review of its gastric cancer drug application.
- +10.0 US regulator gives accelerated review to its gastric cancer filing.
- +10.0 Regulatory clearance for a lung cancer therapy opens a new market.
- +9.7 Described as ahead of European peers on growth and pipeline.
- +9.2 Favourable European regulatory opinion for its product Baxfendy.
- +9.2 Priority review granted by US regulator for its cancer drug.
- +9.2 Early regulatory approval of a new product is a positive.
- +7.0 Shares helped by positive tuberculosis drug trial news.
- +6.7 Share price rose, with coverage looking at the cause.
- +6.7 Japanese designation for a rare-tumour drug, with recent share gains.
- +6.3 Special regulatory designation in Japan supports a pipeline drug.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.